Zim Laboratories Share Price
137.82+4.26 (+3.19%)
+81.65% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
ZIMLABNSE
Zim Laboratories Share Price
137.82+4.26 (+3.19%)
+81.65% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 3% | 4% | -2% | -1% |
| 1% | -4% | -38% | -52% |
| - | - | 4% | 76% |
| 9% | 7% | 5% | 2% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
ZIMLAB
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,849.9 | ₹447476 Cr | 37 | 12.07 | 62.82 | ₹11479 Cr |
| 9,602 | ₹254764 Cr | 87.1 | 34.04 | 128.41 | ₹2568 Cr |
| 4,928.5 | ₹189423 Cr | 86.85 | 16.72 | 97.06 | ₹2163 Cr |
| 1,180.3 | ₹116658 Cr | 25.85 | 9.42 | 62.53 | ₹5040 Cr |
| 1,399 | ₹111484 Cr | 33.08 | 9.77 | 57.87 | ₹3879 Cr |
| 2,026.2 | ₹109943 Cr | 100.55 | 6.8 | 29.25 | ₹889 Cr |
| 2,500 | ₹101712 Cr | 49.79 | 13.75 | 71.08 | ₹1913 Cr |
| 1,200.4 | ₹101005 Cr | 31.35 | 5.32 | 63.99 | ₹4196 Cr |
| 1,716 | ₹99253 Cr | 26.73 | 17.95 | 96.84 | ₹3505 Cr |
| 2,100.7 | ₹96031 Cr | 17.37 | 30.95 | 154.35 | ₹5333 Cr |
| 137.82 | ₹722 Cr | 195.34 | -0.75 | 4.51 | ₹6 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹54 Cr | ₹49 Cr | ₹49 Cr | ₹49 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
| ₹2 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹36 L | ₹1 Cr | ₹59 L | ₹71 L | ₹63 L | ₹0 |
| ₹240 Cr | ₹202 Cr | ₹190 Cr | ₹152 Cr | ₹159 Cr | ₹145 Cr | ₹137 Cr | ₹134 Cr | ₹128 Cr | ₹110 Cr | ₹90 Cr | ₹86 Cr |
| ₹240 Cr | ₹202 Cr | ₹190 Cr | ₹152 Cr | ₹159 Cr | ₹145 Cr | ₹137 Cr | ₹134 Cr | ₹128 Cr | ₹110 Cr | ₹90 Cr | ₹86 Cr |
| ₹296 Cr | ₹252 Cr | ₹239 Cr | ₹200 Cr | ₹176 Cr | ₹161 Cr | ₹154 Cr | ₹151 Cr | ₹137 Cr | ₹118 Cr | ₹99 Cr | ₹94 Cr |
| ₹5,000 | ₹5,000 | ₹3,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹42 Cr | ₹40 Cr | ₹36 Cr | ₹25 Cr | ₹19 Cr | ₹22 Cr | ₹27 Cr | ₹19 Cr | ₹16 Cr | ₹27 Cr | ₹34 Cr | ₹37 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹41 L | ₹3 Cr | ₹4 Cr | ₹77 L | ₹77 L | ₹82 L |
| ₹10 Cr | ₹11 Cr | ₹10 Cr | ₹5 Cr | ₹36 L | -₹3 Cr | -₹5 Cr | -₹2 Cr | -₹4 Cr | -₹9 Cr | ₹0 | ₹0 |
| ₹83 L | ₹2 Cr | ₹3 Cr | ₹1 Cr | ₹72 L | ₹17 L | ₹63 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹1 L | ₹0 | ₹10 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹52 Cr | ₹53 Cr | ₹49 Cr | ₹30 Cr | ₹20 Cr | ₹19 Cr | ₹23 Cr | ₹20 Cr | ₹17 Cr | ₹18 Cr | ₹35 Cr | ₹38 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹73 Cr | ₹70 Cr | ₹62 Cr | ₹58 Cr | ₹81 Cr | ₹65 Cr | ₹66 Cr | ₹72 Cr | ₹66 Cr | ₹45 Cr | ₹47 Cr | ₹64 Cr |
| ₹52 Cr | ₹41 Cr | ₹41 Cr | ₹29 Cr | ₹45 Cr | ₹31 Cr | ₹27 Cr | ₹39 Cr | ₹25 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr |
| ₹62 Cr | ₹52 Cr | ₹55 Cr | ₹23 Cr | ₹17 Cr | ₹45 Cr | ₹50 Cr | ₹40 Cr | ₹50 Cr | ₹47 Cr | ₹56 Cr | ₹51 Cr |
| ₹4 Cr | ₹5 Cr | ₹80 L | ₹59 L | ₹4 Cr | ₹1 Cr | ₹1 Cr | ₹6 Cr | ₹43 L | ₹3 Cr | ₹4 Cr | ₹2 Cr |
| ₹191 Cr | ₹168 Cr | ₹159 Cr | ₹111 Cr | ₹147 Cr | ₹142 Cr | ₹143 Cr | ₹156 Cr | ₹141 Cr | ₹113 Cr | ₹124 Cr | ₹134 Cr |
| ₹540 Cr | ₹473 Cr | ₹447 Cr | ₹342 Cr | ₹343 Cr | ₹322 Cr | ₹320 Cr | ₹328 Cr | ₹295 Cr | ₹250 Cr | ₹257 Cr | ₹266 Cr |
| ₹10 Cr | ₹5 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹4 Cr | ₹3 Cr |
| ₹123 Cr | ₹112 Cr | ₹106 Cr | ₹59 Cr | ₹51 Cr | ₹81 Cr | ₹90 Cr | ₹77 Cr | ₹81 Cr | ₹81 Cr | ₹96 Cr | ₹93 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹290 Cr | ₹275 Cr | ₹267 Cr | ₹199 Cr | ₹180 Cr | ₹165 Cr | ₹159 Cr | ₹136 Cr | ₹113 Cr | ₹98 Cr | ₹120 Cr | ₹108 Cr |
| ₹128 Cr | ₹111 Cr | ₹106 Cr | ₹90 Cr | ₹75 Cr | ₹59 Cr | ₹43 Cr | ₹30 Cr | ₹19 Cr | ₹9 Cr | ₹28 Cr | ₹20 Cr |
| ₹162 Cr | ₹164 Cr | ₹161 Cr | ₹109 Cr | ₹106 Cr | ₹107 Cr | ₹116 Cr | ₹106 Cr | ₹94 Cr | ₹89 Cr | ₹92 Cr | ₹87 Cr |
| ₹59 Cr | ₹44 Cr | ₹24 Cr | ₹18 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹8 Cr | ₹5 Cr | ₹3 Cr | ₹3 Cr | ₹6 Cr |
| ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L |
| ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L | ₹5 L |
| ₹5 Cr | ₹5 Cr | ₹16 Cr | ₹14 Cr | ₹12 Cr | ₹11 Cr | ₹10 Cr | ₹12 Cr | ₹18 Cr | ₹3 Cr | ₹6 Cr | ₹4 Cr |
| ₹29 L | ₹51 L | ₹31 L | ₹52 L | ₹28 L | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹16 L | ₹48 L | ₹28 L |
| ₹263 Cr | ₹241 Cr | ₹219 Cr | ₹151 Cr | ₹129 Cr | ₹130 Cr | ₹138 Cr | ₹132 Cr | ₹122 Cr | ₹96 Cr | ₹102 Cr | ₹97 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹94 Cr | ₹86 Cr | ₹81 Cr | ₹54 Cr | ₹75 Cr | ₹54 Cr | ₹56 Cr | ₹55 Cr | ₹52 Cr | ₹35 Cr | ₹38 Cr | ₹46 Cr |
| ₹109 Cr | ₹107 Cr | ₹100 Cr | ₹95 Cr | ₹90 Cr | ₹72 Cr | ₹68 Cr | ₹93 Cr | ₹89 Cr | ₹88 Cr | ₹89 Cr | ₹81 Cr |
| ₹43 Cr | ₹2 Cr | ₹10 Cr | ₹8 Cr | ₹5 Cr | ₹8 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹8 Cr |
| ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹47 L |
| ₹27 Cr | ₹34 Cr | ₹33 Cr | ₹32 Cr | ₹42 Cr | ₹55 Cr | ₹52 Cr | ₹43 Cr | ₹28 Cr | ₹24 Cr | ₹21 Cr | ₹34 Cr |
| ₹277 Cr | ₹232 Cr | ₹228 Cr | ₹191 Cr | ₹214 Cr | ₹192 Cr | ₹182 Cr | ₹195 Cr | ₹173 Cr | ₹154 Cr | ₹155 Cr | ₹169 Cr |
| ₹85 Cr | ₹65 Cr | ₹68 Cr | ₹80 Cr | ₹66 Cr | ₹50 Cr | ₹39 Cr | ₹39 Cr | ₹32 Cr | ₹41 Cr | ₹32 Cr | ₹35 Cr |
| ₹540 Cr | ₹473 Cr | ₹447 Cr | ₹342 Cr | ₹343 Cr | ₹322 Cr | ₹320 Cr | ₹328 Cr | ₹295 Cr | ₹250 Cr | ₹257 Cr | ₹266 Cr |
| ₹55 | ₹51 | ₹49 | ₹41 | ₹108 | ₹99 | ₹95 | ₹93 | ₹169 | ₹146 | ₹123 | ₹118 |
| ₹55 | ₹51 | ₹49 | ₹41 | ₹36 | ₹33 | ₹32 | ₹31 | ₹28 | ₹24 | ₹20 | ₹20 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹8 Cr | ₹18 Cr | ₹24 Cr | ₹35 Cr | ₹21 Cr | ₹15 Cr | ₹7 L | ₹22 Cr | ₹25 Cr | ₹17 Cr | ₹5 Cr | -₹27 Cr |
| ₹29 Cr | ₹34 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹26 Cr | ₹26 Cr | ₹24 Cr | ₹13 Cr | ₹21 Cr | ₹29 Cr | ₹51 Cr |
| ₹16 Cr | -₹12 Cr | -₹27 Cr | -₹12 Cr | ₹7 Cr | -₹8 Cr | ₹56 L | -₹10 Cr | ₹3 Cr | -₹4 Cr | -₹11 Cr | -₹17 Cr |
| ₹53 Cr | ₹40 Cr | ₹19 Cr | ₹45 Cr | ₹50 Cr | ₹33 Cr | ₹27 Cr | ₹36 Cr | ₹41 Cr | ₹35 Cr | ₹23 Cr | ₹8 Cr |
| ₹50 Cr | ₹41 Cr | ₹16 Cr | ₹38 Cr | ₹49 Cr | ₹32 Cr | ₹22 Cr | ₹35 Cr | ₹37 Cr | ₹32 Cr | ₹22 Cr | ₹6 Cr |
| -₹56 Cr | -₹40 Cr | -₹73 Cr | -₹36 Cr | -₹15 Cr | -₹6 Cr | -₹19 Cr | -₹21 Cr | -₹26 Cr | -₹7 Cr | -₹12 Cr | -₹9 Cr |
| ₹28 Cr | -₹9 Cr | ₹60 Cr | ₹55 L | -₹33 Cr | -₹26 Cr | -₹2 Cr | -₹15 Cr | -₹10 Cr | -₹25 Cr | -₹10 Cr | -₹3 Cr |
| ₹21 Cr | -₹8 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | -₹38,000 | ₹35 L | -₹90 L | ₹1 Cr | -₹32 L | -₹14 L | -₹7 Cr |
| ₹2 Cr | ₹10 Cr | ₹6 Cr | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹50 L | ₹1 Cr | ₹42 L | ₹74 L | ₹88 L | ₹7 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹34,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹2 Cr | ₹22 L | ₹38 L | ₹49 L | ₹36 L | -₹6 L | ₹61 L | -₹7 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹25 Cr | ₹2 Cr | ₹10 Cr | ₹6 Cr | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹50 L | ₹1 Cr | ₹42 L | ₹74 L | ₹88 L |
Fundamental Ratios
Consolidated
Standalone
Zim Laboratories Share Price
137.82+4.26 (+3.19%)
+81.65% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 2 out of 9 oscillators
RSI
61.53Buy
STOCH %K
65.33Neutral
MACD Level(12,26)
4.18Buy
Ultimate Oscillator
58.56Buy
Aroon Oscillator
40.00Sell
BOP
0.46Buy
CCI
101.94Sell
Williams %R
-34.67Neutral
Momentum
9.80Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
134.72Buy
SMA 9
135.76Buy
EMA 21
131.14Buy
SMA 21
131.19Buy
EMA 50
124.32Buy
SMA 50
122.34Buy
EMA 200
103.86Buy
SMA 200
94.25Buy
WMA 20
133.79Buy
Pivot
Pivot
Classic
Resistance 5
153.57
Resistance 4
148.52
Resistance 3
143.47
Resistance 2
138.42
Resistance 1
135.99
Pivot
133.37
Support 1
130.94
Support 2
128.32
Support 3
123.27
Support 4
118.22
Support 5
113.17
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Zim Laboratories Share Price
137.82+4.26 (+3.19%)
+81.65% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 30.36% | 30.35% | 33.26% | 33.26% | 33.26% | 33.26% |
| 0.03% | 0.00% | 0.02% | 0.00% | 0.03% | 0.01% |
| 0.27% | 0.00% | 0.12% | 0.16% | 0.16% | 0.16% |
| 1.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 68.27% | 69.65% | 66.60% | 66.58% | 66.55% | 66.57% |
Bulk & block deals
Name
Elimath Advisors Private Limited
Elizabeth Mathew
Ajit Ramkaran Sarda
Ajit Ramkaran Sarda
Elimath Advisors Private Limited
Mathew Cyriac
Mathew Cyriac
Elizabeth Mathew
Yuga Stocks And Commodities Private Limited
Yuga Stocks And Commodities Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 11 Nov 2025 | Purchase | 28.21 Cr | ₹73.47 | 38.40 L | Bulk | 7.156369 | NSE |
| 11 Nov 2025 | Sell | 28.20 Cr | ₹73.45 | 38.40 L | Bulk | 7.156369 | NSE |
| 29 Oct 2025 | Purchase | 2.17 Cr | ₹81.58 | 2.65 L | Bulk | 0.494764 | NSE |
| 29 Oct 2025 | Sell | 1.17 Cr | ₹82.02 | 1.43 L | Bulk | 0.266299 | NSE |
| 24 Oct 2025 | Purchase | 10.30 Cr | ₹68.79 | 14.97 L | Bulk | 2.790097 | NSE |
| 24 Oct 2025 | Sell | 10.80 Cr | ₹68.84 | 15.69 L | Bulk | 2.924047 | NSE |
| 17 Jul 2025 | Purchase | 20.69 Cr | ₹115.31 | 17.94 L | Bulk | 3.343366 | NSE |
| 17 Jul 2025 | Sell | 20.69 Cr | ₹115.31 | 17.94 L | Bulk | 3.343366 | NSE |
| 20 Mar 2025 | Purchase | 41.75 L | ₹99.73 | 41.86 K | Bulk | 0.07801 | NSE |
| 20 Mar 2025 | Sell | 4.46 Cr | ₹93.51 | 4.77 L | Bulk | 0.889553 | NSE |
Insider trading & SAST
Client name
Dr Anwar Daud
Dr Anwar Daud
Mathew Cyriac & Pacs
Mathew Cyriac & Pacs
Mathew Cyriac & Pacs
Mathew Cyriac
Mathew Cyriac
Mathew Cyriac
Zakir Vali
Mathew Cyriac
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 Jul 2026 | Other | Acquisition | 0.15 | — | 0 | — | 80 K | 11 Jun 2026 | - | — | SAST | 10(6) | — |
| 14 Jul 2026 | Promoter | Acquisition | 0.15 | — | 0 | — | 80 K | 11 Jun 2026 | — | — | SAST | 10(5) | — |
| 12 May 2026 | Other | Acquisition | 7.5 | 19.34 | 0 | — | 40.13 L | 13 Mar 2026 | Market | 1,03,48,766 | SAST | 29(2) | — |
| 08 Mar 2025 | Other | Disposal | 1.83 | 13 | 0 | — | 8.89 L | 10 Feb 2025 | Market | 63,36,064 | SAST | 29(2) | — |
| 17 Oct 2024 | Other | Acquisition | 0.25 | 14.83 | 0 | — | 1.24 L | 03 Sep 2024 | Market | 72,25,498 | SAST | 29(2) | — |
| 10 Apr 2024 | Other | Disposal | 2.4 | 14.58 | 0 | — | 11.71 L | 27 Mar 2024 | Market | 71,01,800 | SAST | 29(2) | — |
| 13 Nov 2023 | Other | Disposal | 2.17 | 16.97 | 0 | — | 10.57 L | 07 Nov 2023 | Market | 82,72,660 | SAST | 29(2) | — |
| 09 Aug 2023 | Other | Disposal | 2.72 | 19.14 | 0 | — | 13.23 L | 04 Aug 2023 | Market | 93,29,527 | SAST | 29(2) | — |
| 27 Jun 2023 | Other | Disposal | 7.18 | 10.36 | 0 | — | 35 L | 12 Jun 2023 | Market | 50,47,420 | SAST | 29(2) | — |
| 29 Mar 2022 | Other | Disposal | 21.86 | — | 0 | — | 35.51 L | 23 Mar 2022 | Market | — | SAST | 29(1) | — |
Zim Laboratories Share Price
137.82+4.26 (+3.19%)
+81.65% past 1 Year
ZIM Laboratories is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. The company has a comprehensive
Corporate Actions
Date
Type
Details
Company details
Zim Laboratories Share Price
137.82+4.26 (+3.19%)
+81.65% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Zim Laboratories Share Price
137.82+4.26 (+3.19%)
+81.65% past 1 Year
News
Zim Laboratories Q1 FY earnings show sharp EBITDA and margin compression
Equity
ZIMLAB
Zim Lab reports wider first quarter loss as revenue rises sharply
Equity
ZIMLAB
Zim Laboratories informs about newspaper advertisements
Equity
ZIMLAB
Zim Laboratories informs about newspaper publication
Equity
ZIMLAB
ZIM Laboratories secures marketing authorization for ‘Dabigatran Etexilate’ in Italy
Equity
ZIMLAB
Zim Laboratories - Quaterly Results
Equity
ZIMLAB
Zim Laboratories reports Profit after tax of 3.28 Crores, in the March 2026 quarter
Equity
ZIMLAB
Zim Laboratories reported sharp year-on-year decline in Q4 EBITDA and margin performance
Equity
ZIMLAB
Zim Laboratories Q4 FY earnings show softer profit and revenue performance YoY
Equity
ZIMLAB
Zim Laboratories informs about acquisition of equity shares of ZIMTAS
Equity
ZIMLAB
ZIM Laboratories invests Rs 89.45 lakh in ZIMTAS
Equity
ZIMLAB
Zim Laboratories informs about disclosure
Equity
ZIMLAB
Zim Laboratories informs about proceedings of EGM
Equity
ZIMLAB
Zim Laboratories gets nod to incorporate subsidiary in Chile
Equity
ZIMLAB
Zim Laboratories reports Profit after tax of 4.26 Crores, in the December 2025 quarter
Equity
ZIMLAB
Zim Laboratories informs about outcome of board meeting
Equity
ZIMLAB
Zim Laboratories Board Approves Issuance of Up to 47,64,497 Shares at Rs 73.46 to Florintree Trinex LLP.
Equity
ZIMLAB
Zim Laboratories informs about press release
Equity
ZIMLAB
ZIM Laboratories gets CDSCO’s approval for Naproxen plus Esomeprazole Capsules
Equity
ZIMLAB
Zim Laboratories informs about conference call
Equity
ZIMLAB

